Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIdox Group Regulatory News (IDOX)

  • There is currently no data for IDOX

Trading Statement

16 Nov 2022 07:00

RNS Number : 5282G
IDOX PLC
16 November 2022
Β 

16 November 2022

Idox plc

('Idox',Β theΒ 'Group'Β orΒ theΒ 'Company')

Year End Trading Update

A resilient performance

Β 

Idox plc (AIM: IDOX), a leading supplier of specialist information management software and solutions to the public and asset intensive sectors, today issues a trading update for its financial year ended 31 October 2022 ('FY22').

Β 

Β 

Group trading performance

Β 

We are pleased to report Idox has delivered a resilient performance for FY22 against a backdrop of economic uncertainty. We have continued to make progress towards a number of our medium-term strategic goals, putting the Group on a strong footing for the future.

Β 

Our focus on winning and retaining long-term recurring revenue contracts with high quality customers has resulted in record full year order intake in excess of c. Β£74m, up 19% on FY21, providing good visibility into FY23.

Β 

The Board expects to report (subject to audit) a c. 15% increase in full year adjusted EBITDA to c. Β£22.5m, in line with management's expectations. Revenue is expected to be up 6% to c. Β£66m, and recurring revenue is anticipated to be up c. 12% over the period to c. Β£40.5m. As a result, the Group expects to deliver an improved adjusted EBITDA margin of c. 34% (FY21: 31%).

Β 

The Group's net debt at year-end was Β£6.7m, a reduction since 31 October 2021 (Β£8.1m net debt). The Group continues to maintain significant balance sheet flexibility and strength, including a Β£35m revolving credit facility and a Β£10m accordion.

Β 

As reported in early October, Idox acquired Landhawk, a land mapping and GIS data business, for Β£1.5m, including an initial cash consideration of Β£1.1m. Landhawk further strengthens the Group's GIS capabilities following the acquisitions of Aligned Assets, thinkWhere and exeGesIS in FY21. We continue to pursue a number of acquisition opportunities but remain focussed on ensuring strategic alignment whilst maintaining a disciplined approach to valuations.

Β 

We have started FY23 with strong recurring revenue and good levels of contract renewals, a solid order book and a healthy pipeline. As a result, our expectations for FY23 remain unchanged, albeit we remain cognisant of the current economic environment.

Β 

Β 

David Meaden, Chief Executive Officer of Idox commented:

Β 

"We have laid the foundations for sustained success at Idox, and against a challenging macro-economic backdrop, we have delivered a robust set of results.

With recurring revenue and order intake up, we are well positioned to continue our success over the coming years, supported by a strong balance sheet.

Β 

Pleasingly, we have seen significant success in areas of strategic focus, notably with Idox Cloud where we have seen 15 new sales during the period, which bodes well for our future performance.

Β The integration of recent acquisitions into the Group has progressed well and we have made several adjustments to our operating business, building capacity for future growth. I am pleased that our leadership development programme has ensured that all new senior appointees have been internal candidates.

Β 

We have a strong balance sheet position, leaving us well placed for an accretive buy and build programme. This, alongside our accelerating organic growth, will create significant value for shareholders and wider stakeholders going forward."

Β 

Β 

Β 

Β 

Β 

Β 

Notice of results

Β 

The Group expects to report its FY22 results in late January 2023. Management intends to host a results webinar on the day. Please contact MHP Communications to register your interest.

Β 

Β 

Definitions

Β 

Adjusted EBITDA is defined as earnings before amortisation, depreciation, restructuring, acquisition costs, impairment, financing costs and share option costs.

Β 

Net debt is defined as the aggregation of cash, bank borrowings and long-term bond.

Β 

Β 

For further information please contact:

Β 

Idox plc

Chris Stone, Non-Executive Chairman

David Meaden, Chief Executive Officer

Anoop Kang, Chief Financial Officer

Β 

+44 (0) 870 333 7101

investorrelations@idoxgroup.com

Peel Hunt LLP (NOMAD and Broker)

Paul Gillam

Michael Burke

James Smith

Β 

+44 (0) 20 7418 8900

MHP Communications

Reg Hoare

Ollie Hoare

Matthew Taylor

Β 

+ 44 (0) 20 3128 8276

idox@mhpc.com

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TSTFELLFLFLLFBK
Date   Source Headline
24th Apr 20184:32 pmRNSHolding(s) in Company
24th Apr 201810:24 amRNSHolding(s) in Company
23rd Apr 20183:40 pmRNSHolding(s) in Company
19th Apr 20183:58 pmRNSResult of AGM and Board Change
19th Apr 20183:54 pmRNSAGM Statement and Trading Update
19th Apr 20187:00 amRNSAGM Statement and Trading Update
27th Mar 20185:17 pmRNSDirector/PDMR Shareholding
27th Mar 201811:02 amRNSPosting of Annual Report and Notice of AGM
22nd Mar 20185:27 pmRNSHolding(s) in Company
19th Mar 201811:22 amRNSHolding(s) in Company
15th Mar 20185:17 pmRNSVesting of LTIP
8th Mar 20184:43 pmRNSHolding(s) in Company
1st Mar 201812:25 pmRNSDirectorate Change
1st Mar 201811:30 amRNSHolding(s) in Company
1st Mar 20187:00 amRNSFinal Results
20th Feb 201812:24 pmRNSHolding(s) in Company
2nd Feb 20184:12 pmRNSHolding(s) in Company
2nd Feb 20188:58 amRNSHolding(s) in Company
31st Jan 20184:52 pmRNSHolding(s) in Company
25th Jan 201812:34 pmRNSDirector/PDMR Shareholding
5th Jan 20184:40 pmRNSSecond Price Monitoring Extn
5th Jan 20184:35 pmRNSPrice Monitoring Extension
3rd Jan 201810:51 amRNSHolding(s) in Company
27th Dec 20171:48 pmRNSHolding(s) in Company
13th Dec 20177:00 amRNSYear End Update and Board Change
14th Nov 20173:45 pmRNSYear End Trading Update
2nd Nov 20171:31 pmRNSDirector Update
22nd Sep 20172:33 pmRNSExercise of Options and Total Voting Rights
20th Sep 20179:32 amRNSHolding(s) in Company
4th Sep 201710:38 amRNSDirectors' Dealing, Exercise of Options & TVR
1st Sep 20176:16 pmRNSHolding(s) in Company
23rd Aug 20176:06 pmRNSHolding(s) in Company
17th Aug 20177:00 amRNSAcquisition
4th Aug 20174:20 pmRNSDirector and PCA Dealing
14th Jul 20173:52 pmRNSDirector/PDMR Shareholding
6th Jul 20174:35 pmRNSPrice Monitoring Extension
29th Jun 20175:23 pmRNSDirector/PDMR Shareholding and Total Voting Rights
6th Jun 20177:00 amRNSHalf-year Report
18th May 20177:00 amRNSHalf Year Trading Update and Notice of Results
17th May 20174:31 pmRNSHolding(s) in Company
18th Apr 20173:45 pmRNSDirector/PDMR Shareholding and Total Voting Rights
7th Apr 20172:27 pmRNSDirector/PDMR Shareholding
22nd Mar 20179:22 amRNSDirector and PCA Dealing
24th Feb 201712:53 pmRNSResult of AGM
24th Feb 20177:00 amRNSAGM Trading Update
15th Feb 20172:55 pmRNSHolding(s) in Company
14th Feb 20171:24 pmRNSExercise of Options and Total Voting Rights
10th Feb 20173:39 pmRNSDirector/PDMR Shareholding
6th Feb 20176:30 pmRNSDirector/PDMR Shareholding
3rd Feb 20179:48 amRNSDirectors' Dealing, Exercise of Options and TVR

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.